Liangyihui, a China-based digital medical platform focused on oncology and backed by conglomerate Legend Holdings, has collected more than RMB100m ($15.5m) in a series C round led by Qiming Venture Partners, DealStreetAsia reported yesterday.
The round also featured new investors DT Capital Partners, Yuanju Capital Management and Wang Jiaquan’s family office as well as existing backers Redhill Capital and Juhe Capital.
Founded in 2013, Liangyihui operates a digital platform that provides clinical information and resources for cancer patients, hospitals and pharmaceutical companies specialising in oncology. The platform is used by almost 200,000 oncologists and around 300,000 cancer patients.
Following the close of the series C round, Liangyihui will further develop the capabilities of its technology platform to better address the needs of the oncology field.
Redhill Capital invested tens of millions of yuan (RMB10m = $1.4m) in Liangyihui’s series B round in December 2018.
Legend Capital, the venture capital firm spun off from Legend Holdings, provided an undisclosed amount of series A funding in 2015.